Kodiak Sciences (KOD) Stock Looks At A Premium On Its Huge 3 Year Run
Kodiak Sciences Inc. KOD
$107.09
▼ -0.01%
($-0.01)
🔥 High Short Interest
📅 Earnings This Week
Open
$107.25
Prev Close
$107.10
Day Range
$105.75 – $108.26
52W Range
$15.83 – $104.00
Market Cap
$6.73B
Beta
2.01
EPS (TTM)
$-4.19
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-10-04 |
| Shares Out. | 62,850,000 |
| Website | kodiak.com/ ↗ |
| Phone | 13026365400 |
| Employees | 124 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$65.6M |
| Free Cash Flow | -$159.9M |
| Total Assets | $256.8M |
| Total Liabilities | $195.7M |
| Equity | $61.1M |
About Kodiak Sciences Inc.
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
Kodiak Sciences Inc. is a publicly traded company under the ticker symbol KOD on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-11-01)